This inventor holds 1 USPTO granted patent. Top assignee: Minophagen Pharmaceutical Co., Ltd.. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Midori Takeda: Innovator in Glycyrrhizin Research
Introduction
Midori Takeda is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceutical research, particularly in the use of glycyrrhizin and its derivatives. Her work focuses on the inhibition of MCP-1 production, which has important implications for various medical conditions.
Latest Patents
Midori Takeda holds a patent titled "Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors." The objective of this invention is to provide a method for inhibiting MCP-1 production through the administration of glycyrrhizin and its derivatives. This method is particularly beneficial for mammals experiencing increased migration of monocytes or T lymphocytes, or elevated production of IL-10, where inhibition of such increases is desired.
Career Highlights
Midori Takeda is associated with Minophagen Pharmaceutical Co., Ltd., where she continues her research and development efforts. Her innovative approach to utilizing glycyrrhizin has positioned her as a key figure in her field.
Collaborations
Midori has collaborated with notable colleagues, including Tokuichiro Utsunomiya and Fujio Suzuki, to advance her research and explore new applications for her findings.
Conclusion
Midori Takeda's work in glycyrrhizin research exemplifies the impact of innovative thinking in the pharmaceutical industry. Her contributions are paving the way for new therapeutic strategies and enhancing our understanding of MCP-1 production inhibition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile